Search This Blog

Friday, July 12, 2019

Rise in early onset colorectal cancer not aligned with screening trends

A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection. The study is published early online in the Journal of Medical Screening.
CRC incidence rates are declining rapidly in adults older than 55 years in the US, partly because of the widespread uptake of colonoscopy, which can remove precancerous growths, lowering incidence rates. In contrast, CRC incidence in younger adults is rising.
There remains debate whether the rise in incidence in younger adults reflects an actual increase in disease, or rather increased detection as a result of more colonoscopies being performed over time.
To add clarity to this debate, American Cancer Society researchers led by Stacey Fedewa, Ph.D. determined past-year colonoscopy rates among more than 50,000 respondents ages 40-54 in the National Health Interview Survey data. Colorectal cancer incidence rates and incidence rate ratios were calculated based on 18 population-based Surveillance Epidemiology and End Results registries during the same period.
Between 2000 and 2015, past-year colonoscopy rates were fairly stable among people aged 40-44 (remaining under 3%), while colorectal cancer incidence rates increased by 28%. Among those ages 45-49, colonoscopy rates doubled (from 2.5% in 2000 to 5.2% in 2015), while colorectal cancer incidence rates increased by 15%. In those ages 50-54, colonoscopy rates increased by about 2.5 times (from 5.0% to 14.1%), while incidence rates rose 17%.
If the growing incidence of young onset CRCs were a result of more detection, larger increases in early-stage diagnoses would be anticipated because screening is most likely to detect localized disease. To investigate this, researchers examined stage-specific CRC incidence trends from 2000-2015. Increases for localized stage disease occurred in ages 40-44, among whom colonoscopy was stable, but not in ages 45-49, among whom colonoscopy had increased. However, distant stage disease increased in every age group, and was steeper (2.9% per year) than that for localized stage (1.1% per year) in ages 40-44 years.
“The changes in past-year colonoscopy rates did not fully align with the rise in overall and distant stage colorectal cancer incidence rates in all three age groups during the corresponding period,” said Dr. Fedewa. “There were some concordant patterns, like the rise in both colonoscopy and early stage incidence among 50-54 years, but there were also some discordant patterns, such as the lack of increase in colonoscopy among people in their early 40’s to match the increasing rates of CRC in this age group.”
“Future studies should examine reasons for the rising CRC incidence rates in young adults,” the study concludes.
###

Eton hit on CRL to partner Bausch

Eton Pharmaceuticals (NASDAQ:ETONannounces that its partner [a subsidiary of Bausch Health Companies (NYSE:BHC) per a February 19 press release] received a Complete Response Letter (CRL) from the FDA regarding the partner’s marketing application seeking approval for EM-100, an eye drop for the potential treatment of ocular itching associated with allergic conjunctivitis.
Eton says the CRL did not cite the need for additional clinical data but offered no additional information other than stating that a response will be submitted shortly, adding that it remains confident that the agency will approve the product.
The Bausch subsidiary acquired the U.S. rights to EM-100 in February.
ETON is down 13% after hours.

Karyopharm drug tested in ‘industry-first’ approach to brain cancer

Karyopharm’s new drug Xpovio is to be tested in a new type of clinical trial designed to rapidly select individualised treatment combinations for brain cancer.
The unusual phase 0/2 design starts with a preclinical phase in which Xpovio (selinexor) will be tested as part of several drug cocktails for glioblastoma – on a patient-by-patient basis – by scientists from the Ivy Brain Tumor Center in Phoenix, Arizona.
Selinexor – a first-in-class oral XPO1 inhibitor – will initially be given alongside various other new experimental drugs to see which combinations have the greatest potential in the study, described as an ‘industry-first approach’ to drug testing.
The tissue-based testing design can show if a combination is having an impact on a patient’s tumour in as little as seven days, allowing patients to quickly continue onto an advanced trial or switch to a different treatment, says Nader Sanai, a neurosurgical oncologist and director of the Ivy Centre.
Glioblastoma – the cancer that killed US Senators John McCain and Ted Kennedy – is one of the deadliest types of cancer with a median survival of just 14 months, and has proved to be one of the toughest challenges for drug developers.
According to the Ivy Centre, only five drugs have been approved for brain cancer patients in the US since 1982, while in the same timeframe more than 50 have been approved to treat lung cancer patients.
Xpovio is variously described as a selective inhibitor of nuclear export (SINE) or an ‘exportin’ inhibitor, forcing tumour suppressor proteins such as p53 and p27 to be retained and accumulate in the cell nucleus, resulting in cell death.
It was approved to treat multiple myeloma earlier this month – despite a call for a delay by an FDA advisory committee – and is also in mid- and late-stage testing in lymphoma as well as solid tumours such as liposarcoma and endometrial cancer.
It’s already in a phase 2 trial as a second-line monotherapy in relapsed or refractory glioblastoma patients.
Results in 30 subjects presented at the ASCO congress in June showed that the drug was able to achieve a 10% response rate – including one complete response and two partial responses.
While not impressive at first glance, that is around twice what has been achieved with other drugs and 19% of the group had progression-free survival of six months.
“Selinexor exploits a compelling target in glioblastoma patients, which is why we have selected it as the backbone of a new experimental drug cocktail,” says Sanai.
“Our scientific partnership with Karyopharm…will arrive at a new therapeutic strategy that can be accelerated into the clinic and patients in need.”

Progenics shareholders thumbs down on chairman, director

Preliminary results from Progenics Pharmaceuticals’ (PGNX -0.5%) Annual Meeting showed that Chairman Peter Crowley and board member Michael Kishbauch failed to receive a majority of votes cast supporting their re-election.
Both have submitted contingent resignations pending the certification of the votes.

ProQR up ahead of QR-421a presentation

ProQR Therapeutics N.V. (PRQR +12.9%) is up on slightly higher volume ahead of a presentation on candidate QR-421a in Usher syndrome tomorrow at the Annual Usher Connections Conference in Philadelphia.
QR-421a is an investigational RNA-based therapeutic designed to exclude exon 13 from the USH2A gene’s messenger RNA, thereby removing the mutation that causes retinitis pigmentosa associated with Usher syndrome type 2.
Usher syndrome is an inherited disorder characterized by hearing and vision loss that worsens over time.
Phase 1/2 study is in process with a primary completion date in December.

Mental Health in a Cannabis Nation

Drew Ramsey, MD: Welcome back to our coverage of the American Psychiatric Association annual conference, where we’re celebrating 175 years of psychiatry.
We wanted to focus on cannabis right now. I’m with Dr Deborah Hasin, a professor of epidemiology in psychiatry at Columbia University, and one of our experts on understanding what’s happening in terms of cannabis and substance use in America.
It feels like I’m getting an incredible number of questions in my practice, as I know other clinicians are, about cannabis and cannabidiol (CBD)—whether they can use it and whether it works. Can you tell us what’s changing in that area?
Deborah Hasin, PhD: There are a lot of things changing, actually. If you think back to 30 years ago, there were no states that had legal marijuana use, either for medical or recreational purposes. If you fast-forward to today, two thirds of US citizens now live in states that have legalized medical marijuana and about 25% in states that have legalized recreational marijuana. The number of Americans who think that marijuana is a harmless substance has gone up sharply in the past several years.
It’s certainly a point worth making that while a lot of people can use marijuana safely without harm, just as with drinking alcohol, cannabis is not a risk-free substance. There are risks involved in using it, and we see time trends for some of those risks increasing as the number of Americans using cannabis rises.

Not a Risk-Free Substance

Ramsey: What are the big risks that clinicians need to be aware of? Because I’m often surprised that this doesn’t get discussed as much as I would think.
Hasin: One of the things that is perhaps most obvious, but that not everybody knows about, is the risk for cannabis use disorder. People assume that cannabis is not addictive. Although it may not be as addictive as opioids, for example, there still is a full syndrome of cannabis use disorder, including cannabis withdrawal, which is included now in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). The number of Americans driving under the influence of cannabis is also increasing, which has risks for vehicle crashes. We have new findings coming out that in people with pain, nonmedical cannabis use is increasing, and the association is growing stronger over time. And there is a relationship between using cannabis and developing psychosis, especially among people who have risk factors like a family history of those kinds of problems.
Ramsey: In terms of us screening and trying to better partner with patients, it feels that as a field, we’ve been very risk-averse and really want to focus on the problems. Yet that’s a little out of step with where the public is and where our patients are sometimes. How do you recommend that we talk about the risks, especially when it comes to psychosis?
Hasin: I think acknowledging that cannabis isn’t a horrible substance for everybody is a good starting point, because then it’s acknowledging that there is some room for discussion. But then saying something about the risks and having a meaningful discussion about what those might be could be a good way to at least get a conversation started.

Latest on Patterns of Use and Effects on Mood Disorders

Ramsey: You noted that a quarter of Americans live in states where they have access to legal recreational cannabis. That’s a huge amount going out into the population. What do you think is going to happen in those states?
Hasin: That’s a great question. There haven’t been that many years of data available for recreational marijuana laws, because the first ones were only passed in 2012. So in terms of national data, that’s not that many years. My colleagues and I have a paper that’s under review now. The findings in that show that cannabis use overall in adults, frequent use, near daily use, and cannabis use disorder have increased more in states that enacted recreational laws than in other states. So it suggests that these laws are having an impact.
Ramsey: We talk a lot about the risk in psychotic disorders, but there’s also an effect in mood disorders and comorbidities with other substance use disorders. And for many years, marijuana was framed as this gateway drug. Can you tell us about other disorders and also whether in some ways it does facilitate people getting into other substances?
Hasin: There’s a lot of controversy about that last point. Certainly in adolescence, we started to see a switch over 4 or 5 years ago with tobacco no longer being the first substance used by teenagers but cannabis being the first substance used. So now people worry about an effect of cannabis acting as a gateway to tobacco.
In regard to other psychiatric disorders, like depressive disorders, if you look at the diagnostic criteria for cannabis withdrawal, a lot of those symptoms are almost exactly the same as symptoms of major depressive disorder. Sometimes people could be using cannabis, thinking that it’s self-treating depression, and what they may actually be experiencing, if they’re using cannabis every day, is that when it wears off, they start to get withdrawal symptoms and it feels like depression. So they use it and those symptoms go away, but they may actually be perpetuating an ongoing withdrawal syndrome. That’s something else for clinicians to think about.
Ramsey: Thank you so much for all of this great information about some of the big changes that are happening in all of our clinical practices, where patients have increasing access, increasing use, and changes in use patterns of cannabis, and the potential risks associated with that. Again, I think we should be encouraged to be flexible when we meet our patients and understand that there are people who can tolerate this and others who can’t. On the clinical side, it’s our job to distinguish who’s who and do our best to get people toward health. Thank you so much.
Hasin: You’re very welcome.

Rise in GI Cancers in Younger Adults: Unraveling the Why

The increase in younger-onset gastrointestinal cancer is creating an ever-growing population of patients who have substantial unmet needs, says an expert.
Irit Ben-Aharon, MD, PhD, Rambam Health Care Campus, Haifa, Israel, called for greater consultation and discussion with these younger adult patients (aged 29 to 49 years) on the role of fertility preservation, as well as on the subsequent risk for cardiovascular morality and issues related to quality of life.
However, she also emphasized that elucidating the “possibly unique biology and etiology” of young-onset gastrointestinal cancer is “essential” if better and more personalized treatments are to be identified in the future.
Speaking here at the World Conference on Gastrointestinal Cancer (WCGC) 2019, Ben-Aharon highlighted recent data that show an increase in incidence in younger adults. She also discussed several possible causes that have been proposed — obesity, antibiotic use, and epigenetic changes related to lifestyle.

Increase in Younger-Onset CRC Incidence

recent analysis of a US population–based cancer registry showed that the incidence of six obesity-related cancers increased significantly among younger adults (aged 25 to 49 years) from 1995 through 2014.
Gastrointestinal cancers accounted for most of those; the incidence of colorectal, pancreatic, gall bladder, and other biliary cancers also increased markedly, Ben Aharon noted. There was an increase in the incidence of gastric noncardia cancer in younger adults, and although this increase was smaller than that for the other GI cancers, the incidence is rising in successively younger generations.
The increase in the incidence of colorectal cancer (CRC) in persons younger than 50 in the United States has been reported widely during the past 2 years, and experts have told Medscape Medical News that this is “an issue screaming for attention.”
study published earlier this year showed that a significant increase in the incidence of CRC in people younger than 50 years has also been reported in many countries in Europe, as well as in Australia, New Zealand, and Canada. The researchers said their data suggest that “there has been a real increase in risk and that the trends do not represent a shift in age at diagnosis attributable to earlier detection.”
In her talk, however, Ben-Aharon pointed out that although this trend has been observed in North America and Western Europe, it is not seen everywhere.
In the Middle East, the picture is more mixed. Cancer rates among younger adults in the Mediterranean tend to be more stable, and in East Asia, cancer rates across age groups are not homogeneous.
With regard to CRC, Ben-Aharon showed results from another recent study of almost 30,000 cases diagnosed among adults aged 40 to 49 years from 1975 to 2015 in the United States.
This study revealed that among younger adults, there were annual percentage increases of CRC of 2.9% for distant disease, 1.4% for localized disease, and 1.3% for regional disease.
These figures suggest that “there has been a real increase in risk,” she commented.
This leads to the question, what is underlying this increase in cancer among young adults?
To date, young-onset cancer has been considered a hallmark of an inherited predisposition to cancer. However, a recent study of 450 patients younger than 50 who had early-onset CRC found that only 16% had hereditary genetic mutations, such as in Lynch syndrome.
This suggests that environmental factors are involved, Ben Aharon commented.

Obesity Increases Risk for CRC

Regarding the reasons for this increase, many researchers have pointed to obesity, which is a known risk factor for cancer.
In her talk, Ben Aharon highlighted two recent studies that suggest that carrying extra weight is associated with an increase in CRC.
study that analyzed data from two large US cohort studies found that, particularly among women, there appeared to be an association between early-life body fatness and CRC risk.
Also, an analysis of data from more than 85,000 women who took part in the Nurses’ Health Study II showed that obese women had almost double the risk for early-onset CRC and that the risk was increased for overweight women compared to women who had a healthy weight (body mass index of 18.5 kg/m2to 22.9 kg/m2).

Increase in Antibiotic Use

One theory that has been put forward to explain the increase in early-onset CRC is that it may be due to a rise in antibiotic use.
Ben-Aharon said that several studies have presented evidence that antibiotic use, particularly long-term use during early to middle adulthood, is associated with an increased risk for CRC, possibly through alterations in the gut microbiome.
Moreover, the use of antibiotics during infancy or childhood, which increased markedly in the 1970s and 1980s, may affect microbial diversity and increase cancer risk.
It is not clear, however, whether the use of antibiotics has a direct effect on early-onset CRC, Ben-Aharon commented.

Epigenetic Changes

Another area of exploration regards epigenetic changes that occur in response to factors such as an increase in the consumption of sugary drinks and foods, increases in pollution levels, or increases in sedentary habits associated with gaming and the use of smartphones.
Although the genomic landscape of early-onset CRC does not differ significantly from that of late-onset disease, there are data that show striking differences in DNA methylation profiles, Ben-Aharon told the audience.
DNA hypomethylation is typically the first epigenetic abnormality that is recognized in human tumors in high-resolution genome-wide studies, although, again, its relevance to early-onset disease is not clear.
The case is different for pancreatic cancer. As Ben-Aharon and colleagues recently reported, in early-onset pancreatic cancer (patients younger than 55 years), the molecular landscape was quite different from that of pancreatic cancer of average-age onset (older than 70 years).
Comparing gene expression in early-onset and average-age-onset pancreatic cancer, they found that there was a host of genes with increased expression in younger-onset disease across several pathways that gave it a highly distinct profile.

“What Is Going On in This Disease?”

After the presentation, Sharlene Gill, MD, professor of medicine, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada, praised Ben-Aharon for offering an “insightful perspective.”
Ben-Aharon was asked whether dietary factors such as folic acid deficiency could contribute to DNA hypomethylation and thereby increase the incidence of early-onset gastrointestinal cancer.
Ben-Aharon replied: “We don’t know much about the biology.
“Compared to pancreatic cancer, for example, in which you can really define pathways, in colorectal cancer, if you look for the patient profile of the genomic signature in the tumor itself, there are subtle changes, but it’s not something very striking.
“But we know that it’s something that probably goes with the environment that may induce epigenetic changes, and hypomethylation may reflect it.”
She added that other possible factors include air pollution, stress, or the microbiome.
To further examine the question, she noted, requires large multinational studies, because the increase in incidence varies between countries and regions.
Only when demographic data are assessed in conjunction with characteristics of normal tissue and diseased tissue; changes in the microbiome; dietary factors; and genetic information from biobanks will researchers possibly “have a clue of what is going on in this disease,” she said.
The investigators have disclosed no relevant financial relationships.
World Conference on Gastrointestinal Cancer (WCGC) 2019. Presented July 4, 2019.